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the risk of chronic kidney disease with con-
secutive cardiac disorders as well as reduced 
overall survival, ablative techniques and active 
surveillance are increasingly applied. In this 
review article we focus on current surgical 
and none-surgical treatment options for the 
management of patients with localized, locally 
advanced, and metastatic renal cell carcinoma.
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Management of localized 
and locally advanced renal tumors. 
A contemporary review of current treatment options
About 70% of patients with renal cell carcino-
ma present with localized or locally advanced 
disease at primary diagnosis. Whereas these 
patients are potentially curable by surgical 
treatment alone, a further 20% to 30% of pa-
tients are diagnosed with primary metastatic 
disease. Although over the past years medical 
treatment for metastatic patients has nearly 
completely changed from immunotherapy 
to effective treatment with targeted agents, 
metastatic disease still represents a disease 
status which is not curable. Also in patients 
with metastatic disease, surgical treatment of 
the primary tumor plays an important role, 
since local tumor related complications can 
be avoided or minimized by surgery. Further-
more, also improvement of overall survival 
has been proven for surgery in metastatic 
patients when combined with cytokine treat-
ment. Hence, surgical combined with system-
ic treatment as a multi-modal, adjuvant, and 
neo-adjuvant treatment is also required in 
patients with advanced or metastatic disease. 
A growing number of elderly and comorbid 
patients are currently diagnosed with small 
renal masses, which has led to increased at-
tention paid to alternative ablative treatment 
modalities as well as active surveillance strat-
egies, which are applied in order to avoid 
unnecessary overtreatment in these patients. 
Since surgical treatment also might enhance 
*For the Renal Cancer Working Group of the Young Aca-
demic Urologists (YAU) working party of the European As-
sociation of Urology (EAU)
Corresponding author: S. Brookman-May, MD, Ludwig-
Maximilians-University Munich (LMU), KlinikumGrosshad-
ern, Department of Urology, Munich, Germany. E-mail: sa-
bine.brookman-may@email.de
Anno: 2013
Mese: June
Volume: 104
No: 3
Rivista: MINERVA MEDICA
Cod Rivista: MINERVA MED
Lavoro: 
titolo breve: Localized and locally advanced renal tumors
primo autore: BROOKMAN-MAY
pagine: 237-59
 
ONCOLOGICAL UROLOGY
MINERVA MED 2013;104:237-59
238 MINERVA MEDICA June 2013
BROOKMAN-MAY LOCALIZED AND LOCALLY ADVANCED RENAL tUMORS
Renal cell carcinoma (RCC) accounts for 2-3% of all cancers in adults in Eu-
rope with an annual increase in incidence 
of about 2% in most European countries 
as well as reduction in incidence rates in 
some others. Approximately 70% of patients 
present with localized or locally advanced 
disease at primary diagnosis and are po-
tentially curable with radical nephrectomy 
(RN) or nephron-sparing surgery (NSS) 
alone. Furthermore, although over the past 
years medical treatment for patients with 
metastatic RCC (mRCC) has nearly com-
pletely changed from immunotherapy to ef-
fective treatment with targeted agents such 
as tyrosine kinase inhibitors (tKI), cure of 
metastatic disease is still not possible. Until 
now, surgical treatment of the primary tu-
morat a local or locally advanced disease 
stage represents the only curative treatment 
option in renal cell carcinoma. Besides sur-
gery for localized RCC, surgical treatment of 
the primary tumor also plays an important 
role in patients with mRCC in order to avoid 
or minimize local tumor related complica-
tions as well as to improve survival which 
has been proven in combination with cy-
tokine treatment. Hence, surgical treatment 
in combination with systemic treatment as 
a multi-modal, adjuvant, and neoadjuvant 
treatment is also required in patients with 
advanced or metastatic disease.
Beneath other reasons, based on en-
hanced sensitivity of modern imaging meth-
ods, a growing number of elderly and in a 
large fraction comorbid patients are diag-
nosed with small renal masses (SRM). Es-
pecially in these patients as well as in those 
with recurrent or multifocal disease and risk 
of chronic kidney disease (CKD), increas-
ing attention is paid to alternative ablative 
treatment modalities such as cryoablation 
(CA) and radiofrequency ablation (RFA) as 
well as to active surveillance strategies (AS). 
Aiming at avoiding unnecessary overtreat-
ment which harbours also an increased risk 
of CKD with consecutive cardiac disorders 
as well as reduced overall survival (OS), 
these techniques are increasingly applied.
In this review article we review the cur-
rent state-of-the-art regarding treatment of 
localized and locally advanced RCC and 
provide a comprehensive overview on cur-
rent evidence regarding surgical as well as 
non-surgical treatment strategies.
Surgical treatment in localized and 
locally advanced renal tumors
Radical nephrectomy
RN has been the standard of care for lo-
calized RCC over the last 50 years. However, 
indication for RN is restricted by two main 
issues. First, incidence of SRM has steadily 
increased. Second, with the improvement 
of NSS according to safety and oncological 
outcome and the development of alterna-
tive ablative treatment strategies, the indica-
tions for RN have decreased. Furthermore, 
novel systemic targeted molecules have an 
impact on timing and sequence of RN in 
either adjuvant or neoadjuvant setting.
RN is defined as a complete removal of 
the tumor bearing kidney. this approach 
has recently been questioned especially for 
smaller (<4 cm) and even larger tumors (4-7 
cm) which present in a location where NS-
Smight be possiblefrom a technical point of 
view.1-3 Besides, almost 20% of SRM are be-
nign. Significant loss of renal parenchyma 
due to RN may predispose patients to CKD, 
which might lead to increased cardiovascu-
lar risk and shorter survival. Currently, RN is 
still indicated for non-metastatic t1 tumors 
when PN is not feasible and in tumors with 
a stage of at least t2.
The role of radical nephrecTomy in T1 renal 
Tumors
Urologic surgeons gradually adapted in-
dications for NSS as a new and more com-
plex procedure initially. thus, primarily NSS 
was reserved for solitary kidneys only. Since 
growing experience showed that NSS had 
equivalent cancer specific survival (CSS) 
compared to RN for tumors <7 cm,1-3 it be-
came the preferred alternative to RN even 
in the elective setting. Besides oncological 
safety, NSS was associated with better pres-
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been reported. Current evidence on differ-
ences between open and laparoscopic as 
well as different laparoscopic approaches 
is inadequate. However, a recent systematic 
review proved that laparoscopic RN offers 
a shorter convalescence time and hospital 
stay, and requires less analgesia than open 
RN.11 the evidence regarding the finest 
choice of approach and type of technique 
between standard, hand-assisted, robot-as-
sisted or single-port is poor and should be 
decided on tumor location, previously per-
formed surgery, surgeon preference, and 
capabilities of the centers.
conTroversial discussion on The role of 
lymphadenecTomy during surgery for lo-
calized renal cell carcinoma
the role of concomitant lymphadenecto-
my (LA) is controversial. two recent studies 
have addressed this issue.12, 13 In the first 
study by Blom et al., patients were ran-
domly allocated to RN plus “not standard-
ized” complete LA or RN alone.12 OS was 
not different between both groups. In an-
other non-randomized study by Herrlinger 
et al., patients underwent RN plus LAif mac-
roscopically abnormal lymph nodes were 
present (facultative LA) or RN plus extend-
ed LA.13 Patients with extended LA had sig-
nificantly better 10-years survival rates com-
pared to patients with facultative LA (80.2% 
vs. 54%). No definitive conclusions on the 
necessity of LA could be derived from avail-
able studies yet. On the other hand, in or-
der to identify patients with indication for 
adjuvant targeted therapy trials, current LA 
practice will probably be modified particu-
larly for high-risk patients in near future.
concomiTanT adrenalecTomy and nephrec-
Tomy
Until now, no randomized study has com-
pared RN alone vs. RN plus adrenalectomy 
(AE). However, one prospective none-ran-
domized study compared PN with AE vs. 
PN without.14 Five-year survival rates were 
not different between groups (82% vs. 85%, 
respectively). tumor size was significantly 
ervation of renal reserve in a systematic re-
view and meta-analysis by Kim et al.4
One European Organization for Research 
and treatment of Cancer randomized trial 
showed NSS not to be inferior to RN with re-
gard to OS, but superiority analysis showed 
that RN was superior to NSS, unexpectedly.5 
Although surgical trials are difficult in terms 
of enrollment and adherence, this study had 
several drawbacks to define the evidence as 
level one. Contrary to that surprising out-
come, already earlier further retrospective 
studies showed that NSS conferred equiva-
lent cancer control and decreased risk of 
overall mortality compared to RN.6, 7 Re-
cently, tan et al. demonstrated that patients 
undergoing NSS were 50% less likely to die 
from any cause. Moreover, after eight years 
of follow-up, 7 NSS instead of RN avoided 1 
death.8 Finally, Kim et al. revealed that NSS 
was associated with a 19% risk reduction in 
all-cause mortality (hazard ratio [HR] 0.81), 
a 29% risk reduction in cancer-specific mor-
tality (HR 0.71), and a 61% risk reduction in 
severe CKD (HR 0.39).4
NSS is now the standard treatment for re-
nal masses up to 7 cm, as recommended by 
European Urology Guidelines.9 Although 
the upper limit of tumor size beyond which 
NSS loses its advantage has yet to be de-
fined, finally in t1 tumors RN is only indi-
cated if NSS is not feasible or in special situ-
ations like RCC combined with end-stage 
renal disease or proven highly aggressive 
tumors (e.g., sarcomatoid, Duct-Bellini and 
medullary carcinoma). Laparoscopic RN in 
t1 tumors appears to have lower comorbid-
ity and equivalent tumor control rates com-
pared to open surgery.
The role of radical nephrecTomy in T2 re-
nal Tumors
Current standard treatment for t2 tumors 
is RN. there is no high quality of evidence 
establishing different RN techniques to be 
superior to others yet. Hence, grade of 
recommendation regarding RN technique 
is low as most studies on that topic suffer 
from small cohorts with a short follow-up.10 
For laparoscopic RN equivalent recurrence-
free survival (RFS) rates and lower morbid-
ity rates in comparison to open RN have 
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death.6 these results underline the clinical 
importance of NSS, even more since almost 
80 % of all renal masses are discovered in-
cidentally, which furthermore will be of be-
nign nature in up to 30% of cases. Finally, 
the way for increased survival of patients 
with metastatic disease is paved by a con-
tinuously evolving armamentarium of tar-
geted therapies, which requires preserved 
renal function in most cases.
According to the 2013 edition of the Eu-
ropean Association of Urology (EAU) guide-
lines on the treatment of RCC, NSS is rec-
ommended for the surgical treatment of t1 
tumors whenever possible. However, NSS 
is also performed for larger tumors, mainly 
for relative and/or imperative indication. 
the respective data available suggests that 
NSS may be also reasonable for advanced 
tumors, but positive surgical margins (PSM) 
and complication rates should be expect-
ed higher in imperative cases compared to 
elective indication.22
A variety of approaches and techniques 
can be used when performing NSS: open 
surgery, laparoscopic and robot-assisted 
minimally invasive approach; wedge resec-
tion, simple enucleation, and enucleore-
section as well as hemi-nephrectomy and 
finally work bench surgery in complex cas-
es. Open and laparoscopic approach yield 
comparable perioperative, clinical, and on-
cologic results, and robot-assisted NSS, oc-
casionally combined with near infrared flu-
orescence imaging, will bring the benefits 
of this minimally invasive approach also to 
patients harbouring complex tumors.23, 24 
Implementation of lasers in the field of NSS 
currently remains reserved for open surgery 
due to the lack of a suitable laparoscopic 
instrumentarium. However, initial reports of 
laser assisted laparoscopic NSShave already 
shown promising results.25
Although NSS is gaining increasing ac-
ceptance, there is still an unfortunate gross 
underutilization of NSS in clinical routine.26 
the underlying reasons are complex and 
seem to include limited patient access to 
high volume institutions as well as a pos-
sible preference of laparoscopic RN over 
open NSS due to shorter convalescence 
predictive of adrenal involvement, which 
was, however, not confirmed in other stud-
ies. Finally, the impact of AE on survival re-
mains to be determined.
radical nephrecTomy in locally advanced 
and meTasTaTic Tumors
Although benefit might be minimal, RN 
as a cytoreductive approach improves sur-
vival in mRCC patients prior to treatment 
with interferon alpha.15, 16 In the last dec-
ade, molecular targeted agents such as 
tKIs, vascular endothelial growth factor 
(VEGF) antibodies, and mammalian target 
of rapamycin (mtOR) inhibitors have led to 
changed treatment paradigms in mRCCpa-
tients. While most phase III studies for tKI 
and VEGFantibodies have actually included 
a high percentage of patients who under-
went RN before treatment with tKI and it 
is generally assumed that data from cytore-
ductive treatment in the immunotherapy 
era can be translated also to patients treated 
with targeted agents, data from randomized 
trials on the definite role for cytoreductive-
andneoadjuvantnephrectomy in the era of 
targeted therapy have to be awaited.17-20 
Likewise, trials testing targeted therapy as 
adjuvant treatment option are underway for 
high-risk patients after surgical treatment.
Nephron sparing surgery and simple enu‑
cleation
During the last decade, NSS evolved from 
an experimental procedure to the surgical 
standard treatment of SRM. Several stud-
ies were able to underline the benefit of 
a better renal function after NSS compared 
to RN.7, 21 Furthermore, as already depicted 
above, the only prospective randomized 
trial for comparison of RN and NSS per-
formed by the EORtC showed oncologi-
cal equity of both procedures.5 As RCC is a 
disease predominantly occurring in the 6th 
and 7thdecade, a significant proportion of 
patients already present with impaired renal 
function. From large scale studies we have 
learned that CKD is a risk factor for car-
diac and vascular events as well asall-cause 
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tive of approach and technique, should be 
performed by an experienced surgeon able 
to adhere to the temporal requirements of 
warm ischemia. Auxiliaries utilized with 
varying evidence to protect renal function 
are intravenous mannitol, inhibitors of an-
giotensin converting enzyme, and topical 
papaverine.32, 33 Finally, advancements in 
the surgical technique, such as the early un-
clamping technique and the use of barbed 
self-retaining running sutures, led to a sig-
nificant reduction of warm ischemia time.
the oncological safety of NSS compared 
to RN was demonstrated in several studies. 
However, positive surgical margins (PSM) 
will be observed in up to 7 % of NSS per-
formed for elective indication and in up to 
18% in imperative indication.34 PSM occur 
irrespective of surgical approach and tumor 
histology. the risk of disease recurrence is 
elevated if a PSM occurs in a highly ma-
lignant tumor, but only the minority of pa-
tients with PSM will experience such tumor 
recurrence.34 therefore, most patients with 
PSM following NSS can be spared sequelae 
of repeat surgery and possible renal func-
tion impairment. these patients should be 
closely monitored, as early salvage therapy 
upon local disease recurrence will be indi-
cated rather than immediate RN. However, 
some controversy is still driven by the trend 
towards a narrowing of the recommended 
surgical margins. Several papers have been 
recently published on the necessary amount 
of normal tissue that should be excised with 
the tumor to avoid the risk of local recur-
rence, concluding that if the tumor is com-
pletely excised, the width of the resection 
margin is irrelevant and not correlated with 
disease progression.35 the EAU Guidelines 
recommend the presence of a minimal tu-
mor-free surgical margin of healthy renal 
tissue surrounding the resected tumor with-
out specifying the exact minimum thickness 
of the healthy parenchyma to be removed.9 
At present, NSS can be performed either as 
standard partial nephrectomy (PN) defined 
as the excision of the tumor and of an ad-
ditional margin of healthy peritumor renal 
parenchyma or as simple enucleation (SE), 
i.e., a tumorectomy done by a blunt dissec-
and better cosmesis, as the more complex 
procedure of laparoscopic NSS may not be 
available at the respective institution. In 
this context, recent data also shows that ro-
bot-assisted NSS (robot-assisted partial ne-
phrectomy; RAPN) is not only effective in 
overcoming the long learning curve of con-
ventional laparoscopic surgery, but thereby 
also may increase the utilization of NSS.27 
Nevertheless, for the moment, open NSS re-
mains the gold standard procedure for NSS.
As one preferential aim of oncologic sur-
gery is to achieve negative surgical margins, 
a wide safety margin of regular renal paren-
chyma surrounding the excised tumor was 
historically recommended: eventually, this 
is no longer necessary. A minimal layer of 
regular renal tissue will provide the onco-
logic safety required, thereby making sim-
ple tumorenucleation and enucleoresektion 
of renal masses possible.28 Margin width 
is irrelevant as long as a negative surgical 
margin is achieved. the surgical technique 
appropriate for the respective tumor may 
be determined by the use of recently pub-
lished scoring systems (Renal nephrometry 
score, Padua score, c-index) which may aid 
in estimating the complexity of a planned 
NSS.
However, all these techniques share the 
same disadvantage: the detrimental ef-
fects of warm ischemia on renal function. 
Although exophytictumors can be excised 
without ischemia, the majority of NSS pro-
cedures will utilize renal artery occlusion to 
improve visibility of the intended resection 
margin. Data available suggests that warm 
renal ischemia should be kept as short as 
possible and irreversible damage may oc-
curs as early as 20 minutes after clamping.29 
Various methods aimed to achieve local hy-
pothermia in NSS, however, they all warrant 
improvement: crushed ice often only cools 
the renal surface while hypothermia needs 
to penetrate into the renal parenchyma suf-
ficiently, and retrograde transureteral per-
fusion cooling of the renal pelvis seems to 
be even less efficient [30]. On the other side, 
renal artery perfusion cooling is highly ef-
ficient but complex and unsuitable for rou-
tine clinical use.31 therefore, NSS, irrespec-
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pathological concerns of incomplete tumor 
excision after SE were analysed in a recent 
study based on pathological examination of 
the surgical specimen obtained after SE that 
described the presence of tissue with a me-
dian thickness of 1 mm lying beyond the 
tumor capsule with signs of chronic inflam-
mation. this precious microscopic layer of 
renal parenchyma allowed the presence of 
negative surgical margins in patients with 
tumors extending beyond the capsule as 
well.44 Increased knowledge within the re-
sults of different renal cancer treatments 
strategies is a prerequisite for advances in 
patients care, however, only a prospective 
randomized study will be able to shed light 
on this dualism, in particular defining the 
best technique of NSS and parameters for a 
correct surgical decision between standard 
PN and SE.the complication rates observed 
with NSS are slightly higher but still very 
tolerable when compared with RN (level of 
evidence: 1b).9, 38 Results regarding morbid-
ity are extremely variable in the literature 
and the overall complication rate after NSS 
ranges between 4% and 37%. Several pre-
dicting factors for postoperative complica-
tions have been reported in the literature, 
the most relevant are: imperative indication 
for NSS, tumor stage ≥t1b (maximal tumor 
dimension >4 cm), perihilar localization of 
the tumor, length of WIt (>20 minutes), en-
dophytictumor growth, and involvement of 
the collecting system.45 Some authors have 
hypothesized that SE might be associated 
with a lower rate of major bleeding and uri-
nary fistula, and, indeed, in a single-center 
series, a low incidence of postoperative 
complications requiring reintervention (3%) 
and also a low rate of urinary fistulas (3%) 
and ureteral stenting (0.5%) was demon-
strated.46, 47 However, no comparative stud-
ied have been published to date to compare 
the morbidity of SE and standard PN and 
therefore it is difficult to draw significant 
conclusions on the differences in adverse 
events rates between the two techniques. 
Finally also for SE, the PADUA score has 
been reported as a reliable toolto predict 
surgical results and morbidity.48
tion, using the natural cleavage plane be-
tween the tumor and normal parenchyma, 
with no ablation of the tumor bed.36 In re-
cent years, considerable data has emerged 
demonstrating good oncologic, functional 
and perioperative outcomes of SE.36-38 In-
deed, many studies have investigated the 
oncological results of SE, demonstrating 
local recurrence-free survival and cancer 
specific survival rates comparable to those 
reported in series of standard PN, for renal 
tumors with clinical diameter up to 7 cm.39-
41 However, no prospective randomized 
studies compared these two techniques 
from an oncological perspective to clarify 
controversies between surgeons about the 
right technique to perform a conservative 
surgery for kidney cancers. While two ret-
rospective studies on large series with long 
FU have compared the oncological results 
to SE versus Standard PN and RN in t1 
patients and showed that SE can achieve 
equivalent oncologic outcomes.36, 38 Re-
ports have also proven reduced incidence 
of positive surgical margins adopting the SE 
technique. this is probably due to the fact 
that SE provides a constant visual detection 
of the correct cleavage plane, whereas the 
sharp excision in case of standard PN can 
sometimes mislead the surgeon, especially 
in case of endophytic tumors. In the large 
multi-center series from SAtURN-LUNA 
project on more than 1500 patients, the inci-
dence of PSM was 3.4% and 0.2% after stan-
dard PN and SE, respectively.36 At contrary, 
opponents to SE cite that a minimal rim of 
normal parenchyma around the resected tu-
mor is recommended to ensure a complete 
tumor removal and reduce the risk of local 
relapse or progression and that the tumor 
capsule that serves as a landmark for SE is 
missing in some tumors.40, 42, 43 Moreover, a 
recent paper also showed that patients who 
underwent SE for Fuhrman grade 4 disease 
had significantly worse cancer specific sur-
vival compared to those undergoing stand-
ard PN, however, this analysis was based on 
too small patient numbers (20 standard PN 
versus 4 SE) to draw an conclusions without 
validation in future prospective trials with 
more patients included.36 the potential 
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and male gender) or related to technique 
(length of ischemia time).56-58
Moreover, CKD was found to be an in-
dependent risk factor for the development 
of cardiovascular events (coronary heart 
disease, heart failure, ischemic stroke, and 
peripheral arterial disease), hospitalization, 
and death of any cause.6 Since from the 
above data one can deduct that RN com-
pared to NSS leads to a higher likelihood 
of CKD, a growing amount of literature has 
aimed to evaluate if patients treated by RN 
have a higher risk of cardiac events and 
lower survival rates.
From the SEER (Surveillance, Epidemiol-
ogy and End Results) registry, Kates et al. 
identified 4216 patients with histologically 
confirmed RCC with a maximum size of 
2 cm, who were treated with NSS or RN. 
When controlling for patient characteristics 
and surgery year, RN was associated with 
reducedOS (HR 2.24) and enhanced cardio-
vascular mortality (HR 2.53).51
Huang et al. addressed the issue of car-
diovascular events and OS by analyzing a 
population-based cohort of 2991 patients 
older than 65 years treated by NSS (19%) 
or RN (81%) for renal cortical tumors <4 cm 
from the SEER-Medicare-linked data regis-
try for the time period between 1995 and 
2002. When controlling for demographic 
characteristics and patient comorbidities, 
type of surgery was not a statistically sig-
nificant predictor of cardiovascular events 
or cardiovascular death. RN, however, was 
associated with an increased risk for al-
cause-death (HR 1.46; P<0.001).59 Contrast-
ing with these results, in the Mayo Clinic 
series, a retrospective analysis based on 648 
patients treated with NSS or RN between 
1989 and 2003 for renal masses smaller than 
4 cm, type of surgery was not significantly 
associated with an increased risk for all-
cause-death. However, in a subset analysis 
limited to patients younger than 65 years, 
RN was associated with decreased OS (HR: 
2.34; P=0.016).54
One further report from Cleveland Clinic 
compared OS, CSS, and cardiac specific sur-
vival in patients undergoing NSS or RN for 
ct1b tumors and reported patients under-
Partial versus radical nephrectomy for cT1 
renal cortical tumors: functional outco‑
mes and impact on overall and cardio‑
vascular mortality
As already specified above, for RCC ≤4 
cm, NSS has become the standard treat-
ment of choice, since it provides excellent 
oncological outcomes and seems to reduce 
the risk of developing chronic kidney dis-
ease (CKD).49-53 NSS has been considered 
as an alternative to RN also in patients with 
tumors>4 cm, who need to preserve renal 
function.49, 50 Moreover, a recently growing 
body of literature has demonstrated that OS 
and CSS will not be compromised when 
NSS is done for 4 to 7 cm renal cortical tu-
mors, adding the benefit of preserving renal 
function.2, 3, 49, 50, 54
Single-institution reports which retro-
spectively compared NSSwith RN in pa-
tients with a normal contralateral kidney by 
using postoperative serum creatinine levels 
as study end point have shown a higher 
likelihood of renal function impairment af-
ter RN. the Mayo Clinic experience using 
a matched comparison of patients who un-
derwent NSS and RN has shown a higher 
risk for chronic renal insufficiency (defined 
as serum creatinine >2 mg/dL) after RN 
(HR 3.7; P=0.01).55 Moreover, Huang et al. 
have analyzed 662 patients who underwent 
elective NSS or RN for <4-cm SRM with a 
normal preoperative serum creatinine and 
a healthy-appearing contralateral kidney 
on imaging. Multivariable analysis indicated 
that RN remained an independent risk fac-
tor for the development of new-onset CKD 
(HR 3.82; P<0.0001).7
the mechanism by which NSS offers an 
advantage over RN in preventing CKD in 
patients with t1 renal masses is certainly 
the result of a greater preservation of the 
nephron capital. Studies looking at inde-
pendent predictors of renal function out-
come after NSS have shown that larger renal 
volume reduction or percentage of resected 
parenchyma adversely influence renal func-
tion after NSS. Further predictors are either 
patient dependent (preoperative estimated 
GFR, solitary kidney status, advanced age, 
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nign renal surgery and for organ confined 
small RCC. Patients benefit from less post-
operative pain and faster return to normal 
activities compared to open surgery, which 
was shown in a randomized controlled trial 
(RCt) by Burgess et al.64 Further advantages 
may be less intraoperative blood loss and a 
shorter hospital stay. At first, the focus of 
laparoscopy was mainly on feasibility and 
on perioperative outcomes. Oncological 
outcome became more important with time 
when this technique was used also for treat-
ment of larger tumors. However, no rand-
omized studies have comparedopen and 
laparoscopic RN with regard to oncological 
oucome yet. Further alternative endoscopic 
approaches for renal cancer surgery, i.e. 
retroperitoneoscopic, hand-assisted lapar-
oscopic, robot-assisted laparoscopic, and 
even single-port laparoscopic techniques 
have recently emerged. When choosing ei-
ther approach, oncological safety is of ut-
most importance. Especially, tumor size, ex-
perience, and surgeon´s preference play an 
important role.
Oncological safety
With regard to oncological safety, for or-
gan confined RCC up to 7 cm (pt1a-pt1b) 
laparoscopy has been proven to be safe. 
Nowadays, in patients with tumors >4 cm 
laparoscopic NSSis being performed in-
creasingly more often with CSS rates equiv-
alent to RN.65 For SRM with a maximum 
size of 4 cm, RN was even found to be sig-
nificantly associated with death from any 
cause compared with NSS.59 In a prospec-
tive cohort study by Hemal et al. for ct2 
RCC, similar oncological outcomes were 
found for laparoscopic and open RN with 
5-year OS rates reported with 87.8% and 
88.7% (P=0.87), respectively.66 there was 
no evidence of any difference in CSS or 
RFS. Furthermore, laparoscopic RN was 
shown to be feasible also for larger tumors 
at advanced stages (pt3), with the expect-
ed advantages of laparoscopy for patient 
recovery, and similar long-term oncological 
outcome in the hands of experienced sur-
geons.67
going RN to loose significantly more renal 
function than those undergoing NSS. the 
average excess loss of renal function ob-
served with RNwas associated with a 25% 
(95% CI 3-73%) increased risk of cardiac 
death and 17% (95% CI 12–27) increased 
risk of death from any cause on multivari-
ableanalysis.2
In summary, current evidence provided 
by literature supports the advantage of NSS 
over RN in reducing the risk of CKD and 
promoting the awareness of the importance 
of kidney preservation. However, the retro-
spective nature of most of the above men-
tioned studies comparing NSS to RN, limits 
the power of their results. Unknown selec-
tion biases may account for the observed 
differences in survival. For example, older 
and female patients are more likely to re-
ceive RN than younger and healthier pa-
tients. Furthermore, patients with multiple 
comorbidities might have been more likely 
to be treated with RN, which could have 
impacted OS results.
Application of different surgical 
techniques for radical nephrectcomy 
and nephron-sparing surgery
Laparoscopic techniques and robot‑assisted 
radical nephrectomy in renal cell carci‑
noma patients
Due to a widespread use of cross-section-
al imaging, incidental diagnosis of SRM is 
frequent and the greatest increase over time 
across RCC tumor stages is among localized 
tumors.60-62 A shift for localized RCC has oc-
curred from open to laparoscopic RN. In 
the first case of laparoscopic which was de-
scribed by Clayman et al. in 1991 a total of 
seven hours operative time was needed.63 
Since then, with more experience also oper-
ative times have decreased significantly. At 
that time the use of this technique for sus-
pected RCC was still controversial and pro-
posed to be most useful for benign disease. 
However, during recent years, laparoscopic 
techniques have improved dramatically and 
quickly became the standard for both be-
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(pt2-t3) in experienced surgeons hands. 
Main patient related advantages include 
less postoperative pain and faster recon-
valescence. New techniques like single-site 
surgery are evolving and may have promis-
ing results for cosmesis and postoperative 
pain, but larger patient series are required 
to confirm this. Robotic surgery for RCC is 
still undergoing further development with 
also increasing use of these techniques not 
only for RN but also for NSS.
Laparoscopic techniques and robot-
assisted nephron-sparing surgery 
in renal cell carcinoma patients
Due to its wide spread use and acceptance, 
open NSS currently remains the contempo-
rary standardtreatment in the management 
of SRM. Nevertheless, based especially on 
invasiveness, postoperative pain, scarring, 
longer hospitalization, and slower convales-
cence with open in comparison to laparo-
scopic techniques, in the forthcoming future 
also NSS procedures will be increasingly ap-
proached by laparoscopic or robot-assisted 
laparoscopic approaches. Firstly described 
by Winfield HN in 1993, laparoscopic NSS 
with several technical variationshas been 
standardized to a great extent during recent 
years.77 Laparoscopic NSS is a viable treat-
ment option with comparable outcomes 
like open surgery with even reduced intra-
operative and postoperative morbidity.78, 79 
Proponents of laparoscopic NSS cite simi-
lar results like open surgery, nevertheless it 
continues to be performed in a minority of 
centersonly due to technical demands dur-
ing the extirpative and in the reconstructive 
step of the procedure and a steep learning 
curve.78-80 Indeed, laparoscopic NSS can of-
fer the advantages of reduced blood loss 
and shorter hospital stay with similar on-
cologic outcomes when compared with the 
open NSS.79 However, this technique has 
also been associated in some retrospective 
observational studies with longer ischemia 
time, increased postoperative complication 
rates, and an increased number of subse-
quent procedures required.23
Different laparoscopic techniques
two RCts comparing retroperitoneo-
scopic and transperitoneal laparoscopic RN 
were performed.68, 69 Although a shorter 
operative time was found for the retro-
peritoneal approach (207 versus 150 min, 
P=0.001) in one study, other perioperative 
outcomes like blood loss, hospital stay, 
complications, analgesia requirements, and 
oncological outcomes were equivalent.68, 69
One quasi RCt and one database review 
compared hand-assisted and transperito-
neal laparoscopic RN.70, 71 No cancer-spe-
cific death or recurrence was reported in 
the first series, however, number of patients 
included was low with 11 patients only in 
each arm, and follow-up was short (medi-
an 20 months).70 Gabr et al. performed a 
multivariable analysis revealing comparable 
5-year RFS, -CSS, and -OS between hand-
assisted and standard laparoscopic RN.71 
Perioperative outcomes were in favour of 
the laparoscopic arm with less blood loss, 
shorter hospital stay, and less time to re-
covery.
One prospective cohort study compared 
laparoscopic and robotic RN for ct1-2 
RCC.72 Perioperative outcomes were com-
parable in both groups, except for opera-
tive time which was significantly longer 
in the robotic group. there were no local, 
port-site or distant recurrences, but again 
follow-up was short and patient numbers 
were low (N.=30).
Only few cohort studies were reported 
on laparoendoscopic single-site RN.73-76 
Cosmetic satisfaction seems better after 
single site surgery. Furthermore, less pain, 
shorter analgesic times, and faster bowel 
recovery were reported. No recurrences or 
port-site metastases occurred during follow-
up. However, patients in these studies had 
ct1 stage RCC, follow-up was short, and 
again patient numbers were small (N.<30). 
Larger patient series are required in order to 
evaluate the real advantages for single port 
surgery, preferably in a randomized trial.
In conclusion, laparoscopic techniques 
for RN are safe for localized RCC and on-
cologically justifiable also for larger tumors 
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Radiofrequency ablation
Technique of RFA
technically, RFA involves a high-frequen-
cy alternating current, 300-500 kHz, which 
induces coagulative necrosis of tumor tis-
sue via needle electrodes.84 Mostly, RFA is 
performed percutaneously under computed 
tomography (Ct) or ultrasound (US) guid-
ance. Monitoring of this procedures difficult 
because neither Ct nor US allows real time 
imaging of the ablation zone. Some authors 
suggest using fiberoptic probes to moni-
tor the procedure and to allow for equal 
radiofrequency energy distribution within 
the tumor.86 the use of RFA is also possible 
during laparoscopic or open interventions.
Advantages and drawbacks of RFA
Percutaneous RFA is one of the mini-
mally invasive treatment options for pa-
tients with renal tumors. Importantly, this 
minimal-invasive approach does not appear 
to negatively affect CSS. the procedure has 
already been performed in many oncologi-
cal centers, and mostly reported treatment 
outcome was satisfactory particularly in the 
management of SRM.87-90 Recently, Psutka 
et al. describe their single-institution expe-
rience with Ct–guided RFA for single, bi-
opsy-proven (t1a and t1b) RCC.87 the au-
thors retrospectively analyzed the outcomes 
of 274 patients with 311 mostly exophytic 
renal masses with a median size of 3 cm. 
Final oncologic outcome was provided for 
185 patients (143 t1a and 42 t1b RCC). RFA 
was shown to be highly efficacious in man-
aging t1a RCC, even over a follow-up of 10 
years. In this group, the authors reported a 
5- and 10-year RFSto be as high as 96% and 
93%, respectively. 5-year DFS and CSS rates 
were 91% and 100%, respectively. Outcome 
of RFA in t1b tumors was less spectacular, 
with a 5-year DFS rate of 74%, suggesting 
that RFA in tumors >4 cm should be consid-
ered only in clinically infirm patients unfit 
for surgery. Similarly encouraging results 
for RFA in t1a tumors were reported by Ol-
weny et al.88 RFA performed in t1a tumors 
First reported in 2004 by Gettman et 
al.81 also RAPNusing the da Vinci Surgical 
System (Intuitive Surgical, Sunnyvale, CA, 
USA), represents an alternative procedure 
to standard laparoscopic open NSS for 
RCC treatment which has steadily gained 
acceptance between surgeons.27 Recently, 
few studies have compared perioperative 
results of RAPN and standard laparoscopic 
NSS, and current evidence suggests that 
RAPN can reproduce the advantages of 
minimal invasiveness with shorter learn-
ing curves and excellent perioperative 
outcomes already after about 30 patient 
cases.82 Recent studies have also shown 
that RAPN can be effectively utilized for 
the treatment of larger renal tumors (>4 
cm) and more complex lesions, such as 
perihilartumors.83 Ideally, every surgical 
option for renal tumors should be com-
pared to open NSS that is the current stan-
dard of treatment and has the robustness 
of data regarding surgical and oncological 
results. Until now, only one prospective 
study has compared perioperative out-
comes of RAPN and open NSS showing 
that RAPN was able to offer comparable 
perioperative and functional outcomes, in-
cluding warm ischemia time and change 
in estimated glomerular filtration rate; fur-
thermore, decreased hospitalization was 
shown for RAPN.84
Ablative treatment options and 
active surveillance strategies
Since a growing number of patients are 
diagnosed with SRM, increasing attention is 
paid to alternative treatment modalities be-
sides surgical treatment. Especially in elder-
ly and comorbid patients as well as in those 
with recurrent or multifocal disease and risk 
of CKD, increasing attention is paid to al-
ternative ablative treatment modalities such 
as CA and RFA as well as to AS strategies. 
Aiming at avoiding unnecessary overtreat-
ment which harbours also an increased risk 
of CKD with consecutive cardiac disorders 
as well as reduced OS, these techniques are 
increasingly applied.
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options, i.e., partial nephrectomy, surveil-
lance, or CA based in prospective studies or 
matched cohorts is currently missing.
In conclusion, recent studies have shown 
that RFA can provide durable oncologic 
control in patients with t1a biopsy-proven 
RCC. therefore, percutaneous RFA remains 
a promising minimally invasive treatment 
approach for appropriately selected pa-
tients with up to 4 cm and at best exophytic 
tumors. Nevertheless, further prospective 
studies are necessary to establish the role 
of RFA as an equivalent to surgery for the 
definitive management of small kidney tu-
mors.
Cryoablation
Widespread use of US and Ct scan has 
increased incidental diagnosis of SRM ≤4 
cm by up to 60%.93 Besides RFA also CA 
represents a minimally invasive technique 
and preferable option to ensure preserva-
tion of renal function and avoid the mor-
bidity associated with surgery. Furthermore, 
CA can be an alternative treatment option 
in patients unfit for surgery and those with 
congenital diseases or renal masses in soli-
tary kidneys.94
Technique of cryoablation
CA is based on the Joule-thomson phe-
nomenon. When tissue and extracellular 
fluid freeze, the osmotic pressure in the ex-
tracellular space increases. the resulting flu-
id shift leads to dehydration, accumulation 
of toxins, change in pH and denaturation of 
proteins. the cellular membrane is disrupt-
ed and the intracellular fluid crystallises; 
the endothelial damage leads to ischemia, 
thrombosis, and coagulative necrosis, end-
ing with cell death.95
CA is delivered through two freeze-thaw 
cycles: a first rapid cycle to -40 °C with the 
formation of an initial ice ball extending up 
to 1 cm beyond the tumour mass, followed 
by a slow-thaw phase. Afterwards, the cycle 
is repeated. the temperature is controlled by 
the placement of thermosensors at the mar-
resulted in 5-year RFS and DFS rates of 92% 
and almost 90%, respectively. Importantly, 
Olweny et al. showed that 5-year OS and 
CSS was similar for RFA and PN, each re-
ported at >95%.
Percutaneous procedures are not only 
more convenient for patients but also lead 
to reduction of morbidity. Complications of 
RFA are rare; the most common include pain 
and paraesthesis and are reported in less 
than 5% of cases. the economic aspects of 
RFA are also encouraging. Hospital stay and 
overall costs are often reduced, mainly be-
cause of a quick recovery. Pandharipande 
et al. described increased cost effectiveness 
of RFA compared with NSS.91 the ease of 
retreatment is another advantage of RFA 
compared with other minimally invasive 
techniques such as CA. Retreatment and/or 
salvage RFA remain possible following the 
incomplete (residual tumor on follow-up 
imaging) or unsuccessful procedure.
the lack of adequate oncologic follow-
up (in many of the large RFA series, the 
reported mean follow-up is generally short 
and does not exceed 3-yrs), the questioned 
accuracy of pre- and postablation biopsy 
(following RFA procedure, the ablated renal 
tumor is left in situ and it is not available 
for complete pathological evaluation), and 
the high rate of benign pathology in SRM 
(around 20-30%) are amongst the main limi-
tations of RFA.Another problematic issue is 
the lack of standardization of RFA, since 
many authors do not provide a detailed 
description of their RFA protocol, which 
limits comparability of different series. Fur-
thermore, follow-up after renal ablative 
therapy remains difficult. there is no per-
fect tool to detect local progression; and, 
according to some studies, the absence of 
contrast enhancement on Ct does not ex-
clude the presence of viable cancer cells.92 
Importantly, the application of a minimally 
invasive approach for treating larger organ-
confined kidney tumors exceeding 4 cm 
remains controversial. According to above 
cited study, outcome for patients with t1b 
tumors undergoing RFA appears unsatisfac-
tory.87 Finally, reliable data on comparative 
effectiveness of RFA and other treatment 
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Different approaches for cryoablation
Minimally invasive CA can be performed 
by the laparoscopic or percutaneous ap-
proach. In case of anterior tumours, the 
laparoscopic approach has the advantage 
of direct visualisation of the tumour, which 
permits use of US to monitor the size of 
the ball and avoid injury to healthy tissue.104 
the laparoscopic approach entails mobili-
sation of the kidney and the perinephric 
fat. Identification of the tumour by US is 
required, and a biopsy should be taken for 
pathology. Use of US also can guide optimal 
placement of the probes. It is recommend-
ed that probes are inserted into the kidney 
at a right angle to minimise the risk of renal 
injury. At the end of the second thaw cycle, 
the probes are gently withdrawn to avoid 
bleeding.
Percutaneous CA offers enhanced advan-
tages in patients with posterior tumours. 
the procedure is usually done under gen-
eral anaesthesia, but in unfit patients also 
local anaesthesia with sedation can be per-
formed instead. US, Ct scan, and MRI can 
be used for tumour localisation, biopsy and 
placement of the probes. A final image can 
be obtained to confirm the precise place-
ment of the probes. the standard double 
freeze-thaw is applied and ice ball formation 
and progression is monitored with real-time 
ultrasonography. A meta-analysis published 
by Hui et al. included 46 series (28 percuta-
neous and 18 surgical) and concluded that 
the percutaneous approach is safer than the 
open or laparoscopic approach, and equally 
effective.105 However, more than one single 
procedure was needed to treat the tumour 
completely.105 Comparing the laparoscopic 
and percutaneous approaches, published 
series have revealed lower rates of blood 
transfusion, shorter hospital stay, and short-
er operative time with the latter, but on the 
other hand, high analgesic requirements.106 
Bandi et al. suggested that percutaneous ab-
lation in carefully selected patients is asso-
ciated with early convalescence compared 
with laparoscopic ablation.107 Also, Mues et 
al. reported lower complication rates and 
no significant change in renal function after 
gins of the tumour or by direct visualisation 
of the ice ball.96 third-generation 17-gauge 
cryoprobes use argon gas, which cools on 
expansion. Probes are available in different 
sizes (1.5-8 mm) and in three shapes (stan-
dard, elliptical and bulb shaped).97
CA for RCC can be performed during 
open surgery as well as laparoscopically 
or percutaneously. Ct scan and MRI are 
the most common imaging techniques for 
follow-up to ensure optimal reduction of 
tumour size and to detect tumorrecurrence 
or persistence. Optimally, Ct scan after 
CA should be performed every 3 months 
for the first 2 years, followed by long-term 
imaging until the lesion has completely re-
solved.98 Stein et al. demonstrated that pres-
ence of enhancement beyond nine months 
after CA is not frequent and furthermore not 
necessarily associated with persistence of 
malignancy.99 Complications of CA include 
bleeding and perinephric hematoma in 
about 10% of cases, which can be avoided 
by slow removal of the probes only during 
the thawing phase.94 Extra-renal complica-
tions include injury to spleen, liver or bow-
el, and paraesthesia at the probe entry site. 
Mid-term follow-up results have confirmed 
that laparoscopic CA iseffective from an on-
cological and functional point of view. In a 
recent series of 100 tumours treated by CA 
with a median follow-up of 30.2 months, 
Beemster et al. reported CSS and metasta-
sis-free survival rates of 100%.100 In a single-
surgeon series of 80 laparoscopic CA, Aron 
et al. reported a CSS rate of 95% after 5 
years and 83% at 10 years, respectively.101
Lin et al. compared laparoscopic NSS and 
CA in patients with multiple ipsilateral tu-
mours. Both patient groups presented with 
similar findings with respect to complica-
tions, renal function, and survival, but the 
laparoscopic NSS group had higher rates of 
blood loss and a longer hospital stay.102 In 
another single-institution report, Desai et 
al. did not observe significant differences 
in hospital stay, blood loss, operating time, 
and complications and recommended lapar-
oscopic NSSas standard treatment based on 
the lack of long-term survival results for CA 
only.103
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AS is defined as initial monitoring of tu-
mor size by serial abdominal imaging (US, 
Ct or MRI) with delayed intervention in 
tumors showing progression during follow-
up. Progression of a SRM during AS is gen-
erally defined as tumor volume doubling 
time <12 months, reaching a tumor diameter 
that is considered to provide risk for devel-
opment of metastasis (3-4 cm) and/or new 
onset of tumor-related symptoms. Several 
experiences have shown that the growth 
rate of SRMs under AS is overall slow and 
progression to metastatic disease is rare (0-
2%) (table I).111-140 Although most reported 
series are retrospective, single institutional 
and relatively small, the results of a large, 
prospective, multi-institutional Canadian tri-
al of AS confirmed a slow growth rate (0.13 
cm/year) and a low tendency to metasta-
size (1.1%) in 209 SRMs followed with serial 
imaging with an average follow-up of 28 
months.112 Other studies have shown that 
delaying intervention does not compromise 
the feasibility of nephron sparing surgery 
and the oncologic outcomes.113
Limitations of current AS series are the 
relatively short follow-up and the lack 
of pathological diagnosis in a significant 
number of cases. Currently, AS is not rec-
ommended for young and healthy patients, 
but is considered an appropriate strategy 
for the elderly or patients with significant 
comorbidities who are not proper surgical 
candidates.49, 114, 115 Gill et al. suggested that 
AS seems also a reasonable option for renal 
masses that are 1 cm in diameter or smaller, 
regardless of patient’s life expectancy.116
there is no clear consensus on the best 
imaging technique and the optimal follow-
CA, with inclusion of patients with a solitary 
kidney.108
to date, CA has not gained widespread 
recognition owing to a lack of long-term 
results. Short- and intermediate-term results 
have shown that CA represents an alterna-
tive treatment option worthy for considera-
tion especially in elderly and unfit patients. 
Initial results of laparoscopic and percuta-
neous approaches can be optimised by em-
ploying the appropriate approach depend-
ing on the location of the tumour, i.e. in 
patients with posterior tumours the percuta-
neous approach should be employed, while 
in those with anterior tumours, laparoscopy 
or single port access should be used.94
Active surveillance and 
percutaneous renal tumor biopsy
Active surveillance for the management of 
small renal masses
the rationale for AS is based on the hy-
pothesis that active treatment for SRM may 
not influence OS in patients with limited 
life expectancy. In fact, recent studies have 
shown that non-RCC related mortality after 
surgical removal of SRMs is significant and 
correlates with age and comorbidities.109, 110 
Lane et al. assessed oncological outcomes 
of a series of 537 patients aged >75 years 
treated either by surgery or observation and 
showed that surgical treatment was not as-
sociated with a significant survival advan-
tage, confirming a role for conservative 
management in selected elderly patients 
and patients with high-risk for surgery who 
present with SRMs.110
Table i.—Outcomes in selected series of patients undergoing active surveillance of small renal masses.
Patients  
(SRMs), n
Mean tumor size 
(cm)
Mean follow-up 
(mo)
Growth rate
(cm/year)
Progression to 
metastasis 
N. (%)
Volpe et al. Cancer 2004 134 29 (32) 2.48 27.9 0.1 0
Chawla et al. J Urol 2006 135 49 (61) 2.97 36 0.2 1 (2)
Abouassaly et al. J Urol 2008 136 110 (-) 2.5 24 0.26 0
Crispen et al. Cancer 2009 137 154 (172) 2.5 31 0.28 2 (1.3)
Rosales et al. J Urol 2010 138 212 (223) 2.8 35 0.34 1 (0.5)
Jewett et al. Eur Urol 2011 139 178 (209) 2.1 28 0.13 2 (1.1)
Patel et al. BJU Int 2012 140 71 (93) 2.2 34 0.21 1 (1.4)
250 MINERVA MEDICA June 2013
BROOKMAN-MAY LOCALIZED AND LOCALLY ADVANCED RENAL tUMORS
imaging, such as oncocytomas and fat-free 
angiomyolipomas.119, 120 Furthermore, per-
cutaneous biopsy can be useful to guide 
surveillance strategies.114, 121 Histologically 
proven, high grade RCCs may not be opti-
mal candidates for AS based on their higher 
risk of progression during follow-up, while 
benign tumors can be followed with a less 
rigorous imaging schedule. Finally, percuta-
neous biopsy should always be performed 
before ablative treatment of a SRM 49, 114 
and can be useful to monitor the success 
of minimally invasive therapies such as RFA 
and CA in combination with Ct and MR im-
aging.
Several issues with renal tumor biopsies 
have still to be resolved. Overall, 3-30% of 
biopsies fail to provide a diagnosis. Further 
improvements in biopsy techniques and in 
the definition of optimal patterns of biopsy 
are required. At present, when a biopsy of a 
radiologically suspicious renal mass is neg-
ative or non-diagnostic, surgical exploration 
or repeat biopsy should be recommended.
Although the diagnosis of histological 
subtype is possible in the majority of RtBs, 
differential diagnosis between oncocytoma 
and chromophobe RCC remains particular-
ly challenging on biopsy specimens.119 the 
use of immunohistochemistry panels, FISH 
and Rt-PCR can increase the accuracy of 
diagnosis in uncertain cases.122, 123 Finally, 
assessment of Fuhrman grading is challeng-
ing on RtBs and accuracy is not optimal. 
this can be partially explained by interob-
server variability and by grade heterogene-
up schedule that should be adopted in AS 
protocols. the typical recommendation is 
to perform repeat imaging at intervals of 
6-12 months.117 Ct and MRI are generally 
preferred based on their superior accuracy 
and lower variability in determining tumor 
size, but there are no studies showing their 
superiority over abdominal US. When US 
visibility of the renal mass is good, it is pos-
sible to alternate cross sectional and US im-
aging to reduce radiation exposure.
the role of percutaneous renal tumor 
biopsy in the management of small renal 
masses by active surveillance and ablative 
treatment strategies
the role of percutaneous renal tumor 
biopsy (RtB) in the management of SRM 
is expanding. Historically, RtBs have been 
rarely used because of concerns about their 
safety and accuracy.118 Several large series 
of RtBs have been recently published, con-
firming that the procedure is characterized 
by low morbidity in centers with expertise. 
Clinically significant bleeding is reported in 
<1% of cases with the use of modern biopsy 
techniques and only 6 cases of renal tumor 
seeding have been reported in the litera-
ture. All recent series of RtBs reported high 
diagnostic rates and excellent accuracy for 
the diagnosis of malignancy (table II).140-148
Aim of biopsy is to determine malignan-
cy, histological type, and grade of a SRM 
in order to support treatment decisions.118 
Needle biopsy can avoid unnecessary sur-
gery for benign renal tumors that cannot be 
accurately identified by modern abdominal 
Table ii.—Outcomes in recent series of patients undergoing percutaneous biopsy of renal tumors.
No. 
tumors
biopsied
Mean 
tumor 
size 
(cm)
Image 
guidance
% 
diagnostic
biopsies
Accuracy for 
malignancy
Accuracy 
for RCC 
subtype
Accuracy 
for grading
Shannon et al. J Urol 2008 141 235 2.9 Ct/US 78% 100% 98% NR
Schmidbauer et al. Eur Urol 2007 142 78 4.0 Ct 97% Sensitivity 93.5%
Specificity 100%
91% 76%
Lebret et al. J Urol 2007 143 119 3.3 Ct/US 79% 86% 86% 46/74%°
Maturen et al. AJR 2007 144 152 4.1 Ct/US 96% Sensitivity 97.7%
Specificity 100%
NR NR
Volpe et al. J Urol 2008 145 100 2.4 Ct/US 84% 100% 100% 66.7/75%
Wang et al. Urology 2009 146 110 2.7 Ct/US 90.9% 100% 96.6% NR
Veltri et al. Eur Radiol 2011 147 103 3.4 US 100% NR 93.2% NR
Leveridge et al. Eur Urol 2011 148 345 2.5 Ct/US 80.6% 99.7% 88% 63.5%
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combination with chemotherapeutic agents 
failed to show oncologic benefit compared 
to observation alone in the adjuvant setting. 
Until now, the only treatment which has 
proven efficacy in the adjuvant setting is an 
autologous tumor vaccine (Reniale®) which 
improvedRFS especially in patients with pt3 
tumors based on results of a randomized 
controlled trial published in 2004.125 How-
ever, until now this substance has not been 
regularly approved based on insufficiencies 
in the trial design (such as missing central 
radiological review and missing adaption 
to the current tNM classification). Further 
adjuvant approaches such as hormonal 
treatment and adjuvant radiotherapy after 
surgery did neither reduce the risk of recur-
rence nor improve survival of patients.126, 
127 In addition, it has to be mentioned that 
in most published studies, except the vac-
cination trials, patients in the trial arms had 
worse prognosis compared with patients in 
the control arms. Finally, outside clinical tri-
als until now no approved adjuvant thera-
peutic approach has been defined. Recent 
advances in understanding the molecular 
biology of RCC led to the development of 
several targeted agents showing impres-
sive anti-tumor efficacy and prolongation 
of PFS in mRCCpatients,128-131 but to date 
no data are available regarding their appli-
cability and efficacy in the adjuvant setting 
after nephrectomy. However, according to 
the established activity of tKI targeting vas-
cular endothelial growth factor (VEGF) and 
platelet-derived growth factor (PDGF) in 
metastatic RCC, currently ongoing phase-III 
trials are exploring the role of these agents 
also in the adjuvant setting aiming at reduc-
ing the risk of tumour recurrence in high-
risk patients after treatment with curative 
intention. Furthermore, different immune-
modulatory characteristics of the tKI suni-
tinib and sorafenib have been shown in vi-
tro, which makes it reasonable to further 
evaluate in vivo immune-modulatory effects 
of these agents.132, 133 However, until results 
from the ongoing phase-III trials are avail-
able it remains unclear, whether treatment 
with antiangiogenic agents will be able to 
enhance RFS after curative treatment. trials 
ity in the tumor. Enhances accuracy in the 
assessment of Fuhrman grade can be ob-
tained when tumors are simply classified as 
low (Fuhrman I-II) or high (Fuhrman III-IV) 
grade.
In summary, adequate biopsies can pro-
vide histological information that can be 
combined with clinical tumor and patient 
characteristics to assist in the choice of the 
appropriate treatment for each individual 
patient. In the future, molecular and cytoge-
netic information from RtBs may be inte-
grated with further histological and clinical 
variables in algorithms and nomograms to 
be used for counseling and treatment deci-
sion-making in patients with SRMs.
Medical treatment in localized tumors
Adjuvant treatment of localized and local‑
ly‑advanced renal tumors after primary 
curative treatment
Approximately 70% of patients present 
with localised or locally advanced disease 
and are curable with surgery or ablative 
treatment alone. Standard therapy of organ-
confined and locally advanced RCC is sur-
gical resection. Additionally, as described 
above, over the recent years further mini-
mally invasive and ablative treatment op-
tions have advanced treatment options in 
RCC patients. However, recurrence rates 
after primary curatively intended treatment 
range between 35-65% depending on sever-
al parameters, including pathological stage, 
Fuhrman nuclear grade, and Eastern Coop-
erative Oncology Group performance status 
(ECOG-PS).124 Data on this issue retrieved 
from several trials clearly demonstrate the 
need for adjuvant treatments for tumor con-
trol, adjusted to the individual oncological 
risk profile.
Contrariwise, until 2004 no adjuvant treat-
ment could reveal efficacy in the adjuvant 
treatment of localized and locally advanced 
RCC. Although treatment with cytokines has 
been the standard treatment for patients with 
mRCC until 2006, adjuvant immunothera-
peutic treatment with cytokines alone or in 
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the primary tumor as well as for metastases 
have changed and previously established 
ways of treatment have been altered.
 — Over the last 50 years, RN has been 
the standard of care for localized RCC, 
however, this approach has recently been 
questioned especially for t1 tumors smaller 
than 4 cm and even for larger tumors. the 
rationale that about 20% of these SRM are 
benign and significant loss of renal paren-
chyma due to RN may predispose patients 
to CKD, increased cardiovascular risk, and 
shorter survival, has led to increasing use 
of NSS in patients with smaller tumors. In 
summary, current evidence provided by the 
literature supports the advantage of NSS 
over RN in reducing the risk of CKD and 
promoting the awareness of the importance 
of kidney preservation. Furthermore, also 
simple enucleation of the tumor displays a 
proper treatment option at least in small le-
sions. However, RN is currently still indicat-
ed for non-metastatic t1 tumors when PN 
is not feasible and in tumors with a stage 
of at least t2 as well as in complex smaller 
tumors.
 — the open approach for RN as well as 
NSS for smaller localized tumors has been 
the standard treatment for several years. Re-
cently also laparoscopic techniques for RN 
have been shown to be safe for localized 
RCC and oncologically justifiable also for 
larger tumors (pt2-t3) when performed 
by experienced surgeons. Main patient re-
lated advantages include less postopera-
tive pain and faster reconvalescence. New 
techniques such as single-site surgery and 
robotic-assisted surgery may further impro-
ve cosmesis and reduce postoperative pain, 
but larger patient series are required to con-
firm this. Due to its wide spread use and 
acceptance, open NSS currently remains 
the contemporary standard treatment in the 
management of SRM. Nevertheless, based 
especially on invasiveness, postoperative 
pain, scarring, longer hospitalization, and 
slower convalescence with open in compar-
ison to laparoscopic techniques, also NSS 
procedures will be increasingly approached 
by laparoscopic or robot-assisted laparo-
scopic approaches, since laparoscopic NSS 
assessing the influence of mtOR inhibitors 
in the adjuvant setting are not available.
Neoadjuvant and multimodal treatment of 
locally‑advanced and metastatic renal 
tumors
Although benefit might be minimal, RN as 
a cytoreductive approach improves survival 
in mRCC patients prior to treatment with 
interferon alpha.15, 16 During the cytokine 
era, the role of cytoreductive nephrectomy 
was defined in order to improve survival 
and to reduce local complications by the tu-
mor. Currently, it is generally assumed that 
data from cytoreductive treatment in the 
immunotherapy era can be translated also 
to patients with mRCC treated with targeted 
agents, which is furthermore corroborated 
by limited retrospective data of smaller pa-
tient series. Furthermore, in most clinical 
phase III trials for tKI and VEGF antibodies 
a high percentage of patients underwent RN 
before treatment with tKI (e.g., for sunitinib 
91% vs. interferon alpha 89%).17 However, 
data from prospective randomized trials 
on the definite role for cytoreductive and 
neoadjuvant nephrectomy as well as on 
multimodal treatment in the era of targeted 
therapy have to be awaited.18, 19 Applying 
systemic therapy prior to surgery could pos-
sibly also guide us to select patients who 
most likely benefit from surgery based on 
response to treatment. Moreover, RN with 
extraction of tumor thrombosis is the only 
chance for survival in patients with locally 
advanced tumor with tumor thrombus in the 
V. cava, which might be facilitated in some 
cases by neoadjuvant treatment only.20 Role 
and timing of application of these novel 
agents in combination with surgical treat-
ment have yet to be defined.
Comment
Over the past few years, treatment op-
tions for localized as well as metastatic RCC 
have expanded. Beside paradigm changes 
in the systemic treatment for metastatic 
disease, also local treatment modalities for 
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lates with age and comorbidities and that 
growth rate of SRMs under AS is overall 
slow and progression to metastatic disease 
is rare.119-122 Further studies have shown 
that delayed intervention does not compro-
mise the feasibility of NSS and deteriorate 
oncologic outcomes.113 However, limita-
tions of current AS series are the relatively 
short follow-up and the lack of pathological 
diagnosis in a significant number of cases. 
Finally, to date AS is not recommended for 
young and healthy patients, but is consid-
ered an appropriate strategy for the elderly 
or patients with significant comorbidities 
who are not proper surgical candidates.49, 
114, 115 Furthermore, there is no clear con-
sensus on the best imaging technique and 
the optimal follow-up schedule that should 
be adopted in AS protocols.
 — the role of percutaneous renal tumor 
biopsy in the management of SRM to as-
sist in the choice of the appropriate treat-
ment for each individual patient and espe-
cially in patients undergoing surveillance 
is expanding. Historically, RtBs have been 
rarely used because of concerns about their 
safety and accuracy.118 Several large series 
of RtBs have been recently published, con-
firming that the procedure is characterized 
by low morbidity and oncological safety in 
centers with expertise. Needle biopsy can 
avoid unnecessary surgery for benign renal 
tumors that cannot be accurately identi-
fied by modern abdominal imaging, such 
as oncocytomas and fat-free angiomyolipo-
mas.119, 120 However, several issues with re-
nal tumor biopsies have still to be resolved. 
Further improvements in biopsy techniques 
and in the definition of optimal patterns of 
biopsy are required, since overall, 3-30% of 
biopsies fail to provide final diagnosis. Al-
though the diagnosis of histological subtype 
is possible in the majority of RtBs, differ-
ential diagnosis between oncocytoma and 
chromophobe RCC as well as assessment of 
grading remains particularly challenging on 
biopsy specimens.119
 — Although benefit for patients might be 
minimal, RN as a cytoreductive approach 
improves survival in mRCC patients when 
combined with systemic treatment with in-
can offer the advantages of reduced blood 
loss and shorter hospital stay with similar 
oncologic outcomes when compared with 
open surgery.79 However, longer ischemia 
time, increased postoperative complica-
tion rates, and an increased number of 
subsequent procedures required should be 
considered as current drawbacks of mini-
mally invasive NSS.23 Recently, few studies 
have also compared perioperative results 
of RAPN and standard laparoscopic NSS, 
and current evidence suggests that RAPN 
can reproduce the advantages of minimal 
invasiveness with shorter learning curves 
and excellent perioperative outcomes also 
in patients with more complex and larger 
tumors.82, 82
 — Since a growing number of elderly 
and comorbid patients are diagnosed with 
SRM, increasing attention is paid to alter-
native treatment modalities besides surgical 
treatment such as CA and RFA as well as to 
AS strategies. Aiming at avoiding unneces-
sary overtreatment which harbours also an 
increased risk of CKD with consecutive car-
diac disorders as well as reduced OS, these 
techniques are increasingly applied. Recent 
studies have shown that RFA can provide 
durable oncologic control in patients with 
t1a biopsy-proven RCC and that it repre-
sents a proper minimally invasive treatment 
approach for appropriately selected patients 
with up to 4 cm and exophytic tumors. An-
other minimal-invasive treatment modality 
is CA, which is currently not widely used 
owing to a lack of long-term results. Short- 
and intermediate-term results have shown 
that CA represents an alternative treatment 
option which should be considered espe-
cially in elderly and unfit patients. Never-
theless, further prospective studies are nec-
essary to establish the role of both RFA and 
CA as an equivalent to surgery for the defin-
itive management of small kidney tumors.
 — the rationale for AS is based on the 
hypothesis that active treatment for SRM 
may not influence OS in patients with lim-
ited life expectancy. this is underlined by 
results of resent studies, which have shown 
that non-RCC related mortality after surgical 
removal of SRMs is significant and corre-
254 MINERVA MEDICA June 2013
BROOKMAN-MAY LOCALIZED AND LOCALLY ADVANCED RENAL tUMORS
In order to individualize treatment on an 
individual patient level, which might fur-
ther improve treatment management and 
patient outcome, in the future integration 
of molecular and cytogenetic information 
from renal tumor biopsies and further his-
tological and clinical variables in algorithms 
and nomograms should be considered for 
patient counseling and improved treatment 
decision-making in RCC patients.
Riassunto
Gestione dei tumori renali localizzati e localmente 
avanzati. Un riesame contemporaneo delle attuali 
opzioni di trattamento
Circa il 70% dei pazienti con carcinoma renale 
presenta una patologia localizzata o localmente 
avanzata alla diagnosi primaria. Mentre tali pazienti 
sono potenzialmente curabili mediante il solo tratta-
mento chirurgico, un ulteriore 20%-30% dei pazienti 
presenta una diagnosi di malattia metastatica pri-
maria. Sebbene negli ultimi anni la cura medica dei 
pazienti metastatici sia quasi completamente pas-
sata dall’immunoterapia al trattamento efficace con 
agenti mirati, la malattia metastatica rappresenta 
ancora una patologia incurabile. Anche nei pazien-
ti con malattia metastatica, il trattamento chirurgico 
del tumore primario svolge un ruolo importante, 
in quanto le complicanze locali correlate al tumo-
re possono essere evitate o minimizzate attraverso 
l’intervento chirurgico. Inoltre, la chirurgia ha dimo-
strato anche il miglioramento della sopravvivenza 
globale dei pazienti metastatici, se abbinata al trat-
tamento con citochina. Quindi, l’intervento chirur-
gico, abbinato alla cura sistemica come trattamento 
multi-modale, adiuvante e neo-adiuvante, è richie-
sto anche in pazienti con malattia avanzata o me-
tastatica. Attualmente un numero crescente di pa-
zienti anziani e comorbidi presenta una diagnosi di 
piccole masse renali e ciò ha comportato una mag-
giore attenzione per modalità alternative di tratta-
mento ablativo, nonché per strategie di sorveglianza 
attiva, applicate in modo da evitare un inutile ac-
canimento terapeutico su questi pazienti. Dal mo-
mento che il trattamento chirurgico potrebbe anche 
aumentare il rischio di malattia renale cronica con 
disturbi cardiaci consecutivi, nonché una riduzione 
della sopravvivenza globale, si applicano sempre di 
più tecniche di ablazione e di sorveglianza attiva. In 
questo articolo ci concentriamo sulle opzioni attuali 
di trattamento chirurgico e non chirurgico per la 
gestione dei pazienti con carcinoma renale localiz-
zato, localmente avanzato e metastatico.
parole chiave: Carcinoma, cellule renali - Nefrecto-
mia - Ablazione, tecniche.
terferon alpha.15, 16 During the last decade, 
molecular targeted agents such as tKIs, 
VEGF antibodies, and mtOR inhibitors 
have led to changed treatment paradigms in 
mRCC patients. Generally it is assumed that 
data from cytoreductive nephrectomy can 
be transferred also to the era of targeted 
treatment. However, data from randomized 
trials on the definite role for cytoreductive 
and neo-adjuvant nephrectomy in the era 
of targeted therapy have to be awaited.17-20
 — trials assessing the effect of targeted 
therapy as adjuvant treatment option after 
surgery in patients with high-risk localized 
and locally advanced tumors are also un-
derway and results might change current 
treatment practice further, since until now 
outside clinical trials no adjuvant treatment 
option is available for RCC patients despite 
considerable recurrence rates after primary 
surgery.
Finally, local treatment in patients with 
localized as well metastatic RCC plays a 
considerable role for adequate patient man-
agement. In the near future, minimally inva-
sive surgical treatment options such as lap-
aroscopic and robot-assisted laparoscopic 
surgery will be increasingly applied based 
on promising results with regard to patient 
related benefits such as cosmesis as well 
equivalent oncological outcome in com-
parison to standard surgical treatment. Also 
ablative treatment options such as CA and 
RFA as well as surveillance strategies might 
be applied more often in order to avoid 
unnecessary overtreatment, development 
of chronic kidney disease, and reduced 
overall survival especially in patients with 
small kidney tumors. For the future, every 
new surgical and ablative treatment option 
for renal tumors needs to show robustness 
with regard to surgical and oncological re-
sults in comparison with the current stan-
dard treatment. For patients with advanced 
and metastatic disease results of prospec-
tive trials assessing the efficacy and role 
of multimodal, neo-adjuvant and adjuvant 
treatment as well as of cytoreductive sur-
gery in the era of targeted treatment have 
to be awaited and might further change 
currently established treatment pathways. 
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